Thiel Capital-backed Alloy Therapeutics raises $42M

Biotechnology company Alloy Therapeutics has raised $42 million, with return investor Thiel Capital participating in the series D fundraising round.

Alloy is a biotech company that works to expedite drug discovery and democratize the drug innovation process. Following Alloy's series C funding round, the company expanded from antibody technology discovery into T-cell receptors, according to the Oct. 3 Alloy news release.

The company plans to use the proceeds from the latest round to fund pre-competitive drug discovery technologies and explore partnerships.

The funding round was led by 8VC and Mubadala Capital, with participation from Thiel Capital, Presight Capital and Founders Fund. 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like